Filtered By:
Source: Cancer Research
Cancer: Squamous Cell Carcinoma
This page shows you your search results in order of date.
Order by Relevance | Date
Total 42 results found since Jan 2013.
Birinapant and Radiation in HNSCC
Comparison of tumors from The Cancer Genome Atlas (TCGA) reveals that head and neck squamous cell carcinomas (HNSCC) harbor the most frequent genomic amplifications of Fas-associated death domain (FADD), with or without Baculovirus inhibitor of apoptosis repeat containing BIRC2 (cIAP1), affecting about 30% of patients in association with worse prognosis. Here, we identified HNSCC cell lines harboring FADD/BIRC2 amplifications and overexpression by exome sequencing, RT-PCR, and Western blotting. In vitro, FADD or BIRC2 siRNA knockdown inhibited HNSCC displaying amplification and increased expression of these genes, supporti...
Source: Cancer Research - September 14, 2016 Category: Cancer & Oncology Authors: Eytan, D. F., Snow, G. E., Carlson, S., Derakhshan, A., Saleh, A., Schiltz, S., Cheng, H., Mohan, S., Cornelius, S., Coupar, J., Sowers, A. L., Hernandez, L., Mitchell, J. B., Annunziata, C. M., Chen, Z., Van Waes, C. Tags: Therapeutics, Targets, and Chemical Biology Source Type: research
Abstract B37: Targeting tumor-stroma metabolic symbiosis for head and neck cancer therapy
Despite aggressive therapies, head and neck squamous cell carcinoma (HNSCC), which affects 50,000 new patients annually in the United States, is associated with less than 50% 5-year survival. HNSCC tumors display increased glycolysis, even in the presence of oxygen. Consequently, there is an increase in lactic acid (LA) production. However, the effect of lactic acid in the tumor microenvironment and the mechanisms whereby HNSCC tumors survive in highly acidic conditions remain unknown. HNSCC consist of up to 80% tumor-associated fibroblasts (TAFs). We previously reported that activation of receptor tyrosine kinase, c-Met, ...
Source: Cancer Research - July 27, 2016 Category: Cancer & Oncology Authors: Kumar, D., Vishwakarma, V., New, J., Gutierrez, W., Chavan, H., Kasturi, P., Tawfik, O., Girod, D., Houten, B. V., Leef, G., Joshi, R., Shelton, S., Straub, J., Shnayder, Y., Kakarala, K., Tsue, T., Lin, F., Dasari, S., Thomas, S. Tags: Tumor Microenvironment and Metabolic Adaptations Source Type: research
Abstract B05: WHSC1L1 and estrogen-independent activation of estrogen receptor-alpha (ER{alpha}) in 8p11 amplicon-bearing cell lines
The 8p11-p12 genomic region is amplified in 15% of breast cancers and 21% of lung squamous cell carcinomas (LSCC) and is associated with poorer prognosis. This genomic region harbors several oncogenes, three of which are epigenetic modifiers of chromatin (WHSC1L1, KAT6A, ASH2L). WHSC1L1 is a histone methyltransferase (HMT) that is expressed in 2 isoforms. The long isoform (WH-long) encompasses the entire coding region and is associated with dimethylation of lysine 36 on histone 3 (H3K36me2) to facilitate transcriptional elongation. The short isoform (WH-short) is produced by alternative splicing at exon 10, resulting in a ...
Source: Cancer Research - January 14, 2016 Category: Cancer & Oncology Authors: Mills, J. N., Irish, J., Turner-Ivey, B., Ethier, S. P. Tags: Cancer Genomics and Epigenomics Source Type: research
Th17 Recruitment via Cervical Cancer-Instructed Fibroblasts
In this study, we demonstrate that CCL20 was predominantly expressed in the stroma of cervical squamous cell carcinomas in situ. This correlated with stromal infiltration of CD4+/IL17+ cells and with advancing International Federation of Gynecology and Obstetrics (FIGO) stage. Furthermore, we show that cervical cancer cells instructed primary cervical fibroblasts to produce high levels of CCL20 and to attract CD4/IL17/CCR6-positive cells, generated in vitro, in a CCL20/CCR6-dependent manner. Further mechanistic investigations identified cervical cancer cell–derived IL6 as an important mediator of paracrine CCL20 inductio...
Source: Cancer Research - December 14, 2015 Category: Cancer & Oncology Authors: Walch–Ruckheim, B., Mavrova, R., Henning, M., Vicinus, B., Kim, Y.–J., Bohle, R. M., Juhasz–Boss, I., Solomayer, E.–F., Smola, S. Tags: Microenvironment and Immunology Source Type: research
Abstract 1428: Targeting RRM2 by siRNA inhibits cellular invasion and represents a rational approach for inhibition of metastasis of head and neck and lung cancers
Background: Ribonucleotide reductase subunit M2 (RRM2) has been frequently observed to be aberrantly overexpressed in various tumors. RRM2 is a key enzyme, and essential regulator of balanced deoxyribonucleotides (dNTPs). It is critical for DNA replication and repair, and hence cell survival. In addition to DNA synthesis, it has been reported to modulate cellular invasiveness. However, the mechanisms through which RRM2 affects the invasive phenotype have not been elucidated.Methods: We evaluated the expression of RRM2 protein in metastatic (n = 40) and non-metastatic (n = 40) head and neck squamous cell carcinoma (HNSCC) t...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Rahman, M. A., Amin, A. R. M. R., Zhang, J., Nannapaneni, S., Saba, N. F., Chen, Z. G., Shin, D. M. Tags: Tumor Biology Source Type: research
Abstract LB-136: The role of ER chaperone GRP94 in endometrial cancer progression
This study expands our understanding of GRP94 function in the progression of solid tumors and provides the first evidence that GRP94 could be a target for combating endometrial cancer.Citation Format: Jieli Shen, Yvonne G. Lin, Louis Dubeau, Amy S. Lee. The role of ER chaperone GRP94 in endometrial cancer progression. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-136. doi:10.1158/1538-7445.AM2015-LB-136
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Shen, J., Lin, Y. G., Dubeau, L., Lee, A. S. Tags: Tumor Biology Source Type: research
Abstract 1724: Integrated functional RNAi screening and structural genomics identify inverse co-modulators of TP53 family and NF-{kappa}B transitional activation as potential therapeutic targets in head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide with a 50-60% mortality rate. Deregulation of p53 family members in HNSCC occurs in over 90% of cases, preventing transcription of growth arrest and apoptosis genes. Conversely, members of the NF-κB/REL family are aberrantly activated in about ∼70% of cases, and drive expression of pro-proliferation, inflammation, angiogenesis, and therapeutic resistance genes. The function of different TP53 and NF-κB family members are inversely modulated within two major subsets of HNSCC, suggesting that common molecules and pathways coordinate this...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Saleh, A., Cornelius, S., Martin, S., Ormanoglu, P., Cheng, H., Das, R., Yang, X., Chen, Z., Van Waes, C. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 744: Transactivation of HER3 via heterodimerization with epidermal growth factor receptor (EGFR) or insulin-like growth factor 1 receptor (IGF-1R) contributes to adaptive resistance to NVP-BKM120 in non-small cell lung cancer (NSCLC) and squamous cell carcinom
Conclusions: Transactivation of HER3 via EGFR or IGF-1R attenuates the effectiveness of NVP-BKM120 in multiple NSCLC and SCCHN cells. Our results suggest that either targeting HER3 directly or indirectly by inhibiting transactivation partners, such as EGFR or IGF-1R, may be potential therapeutic options to overcome adaptive resistance to NVP-BKM120.Note: This abstract was not presented at the meeting.Citation Format: Miran Yun, Jinyoung Sohn, Byoung Chul Cho. Transactivation of HER3 via heterodimerization with epidermal growth factor receptor (EGFR) or insulin-like growth factor 1 receptor (IGF-1R) contributes to adaptive ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Yun, M., Sohn, J., Cho, B. C. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 194: Deregulation of miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced metastatic potential
Chemoresistance often associated with other clinical characteristics, such as enhanced metastatic potential. However, the underlying molecular mechanism remains unclear. Our previous studies had revealed that microRNA-222 (miR-222) regulates the cell invasion [Cancer Genomics Proteomics 2009 6:131-138], and plays a role in cell proliferation in tongue squamous cell carcinoma (TSCC) [FEBS Lett. 2010 584(18):4115-20]. The aim of this study is to elucidate the role of miR-222-ABCG2 pathway in the association of cisplatin (cDDP) resistance with enhanced cell migration and invasion ability in TSCC. First, we confirmed the assoc...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Wang, A., Zhao, L., He, Q., Zhao, T., Wang, W., Zhou, X. Tags: Molecular and Cellular Biology Source Type: research
Abstract 813: Human papillomavirus 16 oncoprotein E6 upregulates c-Met partially through p53 in squamous cell carcinoma of the head and neck
Conclusion: Our results show that c-Met expression is upregulated by HPV E6, which is partially mediated by p53. The data suggest that targeting c-Met may serve as a novel approach for treating HPV-associated OPSCC.(This study was supported by grants from Small Business Innovation Research (SBIR) Program (HHSN261201200097C), National Institutes of Health (R33 CA161873), and National Cancer Institute (NCI P50 CA 128613, Head and Neck SPORE).Citation Format: Guoqing Qian, Dongsheng Wang, Kelly R. Magliocca, Praveen Duggal, Sreenivas Nannapaneni, Sungjin Kim, Zhengjia Chen, Dong M. Shin, Nabil F. Saba, Zhuo G. Chen. Human pap...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Qian, G., Wang, D., Magliocca, K. R., Duggal, P., Nannapaneni, S., Kim, S., Chen, Z., Shin, D. M., Saba, N. F., Chen, Z. G. Tags: Carcinogenesis Source Type: research
Abstract 101: WHSC1L1 as a therapeutic target in squamous cell carcinoma of the head and neck
Conclusions: WHSC1L1 is genetically altered in multiple cancer types. In SCCHN, it is significantly overexpressed in 24% of the tumors and its knockdown caused significant growth suppression of both HPV-positive and HPV-negative SCCHN cell lines. Taken together, WHSC1L1 merits further investigation as a potential therapeutic target in SCCHN.Citation Format: Vassiliki Saloura, Theodore Vougiouklakis, Mark Lingen, Tanguy Seiwert, Everett Vokes, Yusuke Nakamura, Ryuji Hamamoto. WHSC1L1 as a therapeutic target in squamous cell carcinoma of the head and neck. [abstract]. In: Proceedings of the 106th Annual Meeting of the Americ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Saloura, V., Vougiouklakis, T., Lingen, M., Seiwert, T., Vokes, E., Nakamura, Y., Hamamoto, R. Tags: Molecular and Cellular Biology Source Type: research
Abstract 3369: Nuclear hormone receptor profiling of skin cancer-associated fibroblasts for targeted pharmacological modulation of skin squamous cell carcinoma
Background: Cutaneous squamous cell carcinoma (SCC) is the second-most frequently diagnosed non-melanoma skin cancer that commonly manifests in sun-exposed areas of the skin, resulting in permanent disfigurement and potentially death when untreated. The development and malignant progression of skin SCC is dependent not only on the properties of the tumor epithelia but also the effects of the tumor stroma. Cancer associated fibroblasts (CAFs) are enriched in the stroma of skin SCC tumors and supply paracrine factors that encourage tumor growth. However, the transcription regulatory networks enabling this pro-tumor secretory...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Chan, J. S. K., Sng, M. K., Teo, Z. Q., Tan, N. S. Tags: Tumor Biology Source Type: research
Abstract 3616: Development of a Sox2 targeting therapy for the treatment of lung squamous cell carcinoma
Despite the recent development of several effective molecular targeted agents, lung cancer is the most common cause of cancer related deaths worldwide. Recently, molecular targeted therapies for pulmonary adenocarcinoma with mutant EGFR or ALK fusions have reduced non-tumor toxicity and have extended patient survival time compared to conventional chemotherapies. However, the development of molecular targeting drugs for NSCLC has made apparent the fact that histology is an important factor and molecularly targeted therapies have been more effective in pulmonary adenocarcinoma than in lung squamous cell carcinoma. Therefore,...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Ishida, N., Fukazawa, T., Takaoka, M., Yamatsuji, T., Morita, I., Haisa, M., Takaoka, N., Naomoto, Y. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 110: The role of the p53 target Wig-1 in senescence and cancer
The wild type p53-induced gene 1, Wig-1 (also known as Zmat3 or PAG608) binds to AU-rich elements in mRNAs and thereby regulates important tumor associated factors including p53, FAS, and N-Myc.Focusing on normal human diploid fibroblasts (HDF), we are now exploring the role of Wig-1 in senescence. SiRNA-mediated Wig-1 depletion increases senescence markers such as Beta-galactosidase staining, H3K9me3, H4K20me3, and p21. Also, Wig-1 is spontaneously downregulated in cells undergoing replicative senescence.The trimethylation of lysine 9 on histone 3 (H3K9me3) is an established marker of cellular senescence and increases upo...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Jerhammar, F., Bersani, C., Djureinovic, D., Micke, P., Wiman, K. G. Tags: Molecular and Cellular Biology Source Type: research
Abstract 353: Vorinostat enhances anti-tumor effects of cisplatin in head and neck cancer cells by targeting cancer stem cells
Conclusions: Taken together, our results suggest that targeting of HDACs with Vorinostat could be an effective treatment strategy for the treatment of HNSCC patients that do not respond to currently used treatment regimens.Citation Format: Bhavna Kumar, Arti Yadav, Theodoros N. Teknos, Pawan Kumar. Vorinostat enhances anti-tumor effects of cisplatin in head and neck cancer cells by targeting cancer stem cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 353. doi:10...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kumar, B., Yadav, A., Teknos, T. N., Kumar, P. Tags: Tumor Biology Source Type: research
